TY - JOUR
T1 - New drug-development paradigms? Opportunities and uncertainties with new government drug repurposing programmes
AU - Liddicoat, Johnathan
AU - Hamidzadeh , Ashleigh
AU - Liddell, Kathleen
AU - Schito, Marco
AU - Simon, David
AU - Aboy, Mateo
AU - Minssen, Timo
N1 - Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.
PY - 2024/6/26
Y1 - 2024/6/26
N2 - KEY MESSAGES●Governments in the US, UK and EU have recently established seven drug-repurposing programmes that aim to overcome legal and regulatory hurdles.●The programmes all operate in different ways, presenting a variety of opportunities for all organisations in drug development, including charities and academics.●Perhaps more profoundly, at least three of the programmes also constitute new models of drug development, relying less on patents and private industry and more on government involvement and clinical trials run by the public sector.●These new models could lead to relatively fast, inexpensive therapies. Yet, how effective the programmes will be and how they could be improved is uncertain, and the comparison in this paper paves the way to address these essential issues.
AB - KEY MESSAGES●Governments in the US, UK and EU have recently established seven drug-repurposing programmes that aim to overcome legal and regulatory hurdles.●The programmes all operate in different ways, presenting a variety of opportunities for all organisations in drug development, including charities and academics.●Perhaps more profoundly, at least three of the programmes also constitute new models of drug development, relying less on patents and private industry and more on government involvement and clinical trials run by the public sector.●These new models could lead to relatively fast, inexpensive therapies. Yet, how effective the programmes will be and how they could be improved is uncertain, and the comparison in this paper paves the way to address these essential issues.
KW - Faculty of Law
KW - Government Programs
KW - drug R&D
KW - new uses
KW - drug repurposing
KW - Public private partnership
KW - Emperical legal studies
UR - https://www.science.org/doi/10.1126/scitranslmed.adl0998?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
U2 - 10.1126/scitranslmed.adl0998
DO - 10.1126/scitranslmed.adl0998
M3 - Journal article
C2 - 38924430
VL - 16
JO - Science Translational Medicine
JF - Science Translational Medicine
SN - 1946-6234
IS - 753
ER -